Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients?

Passiglia, F.

Risultato della ricerca: Article

Abstract

Nessuno
Lingua originaleEnglish
pagine (da-a)S1413-S1416
Numero di pagine4
RivistaTranslational Cancer Research
Volume5
Stato di pubblicazionePublished - 2016

Fingerprint

Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cita questo

Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients? / Passiglia, F.

In: Translational Cancer Research, Vol. 5, 2016, pag. S1413-S1416.

Risultato della ricerca: Article

@article{9049927b11824b5aac48287d82cf3adf,
title = "Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients?",
abstract = "Nessuno",
author = "{Passiglia, F.} and Antonio Russo",
year = "2016",
language = "English",
volume = "5",
pages = "S1413--S1416",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients?

AU - Passiglia, F.

AU - Russo, Antonio

PY - 2016

Y1 - 2016

N2 - Nessuno

AB - Nessuno

UR - http://hdl.handle.net/10447/284277

UR - http://tcr.amegroups.com/article/download/11308/pdf

M3 - Article

VL - 5

SP - S1413-S1416

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -